Trial reportJournal of the American Heart Association2025
Effect of Time Delay on Reperfusion After Tenecteplase in an Extended Time Window: Analysis From the CHABLIS-T Trials.
Trial report in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Chinese Acute Tissue-based Imaging Selection for Lysis in Stroke: a Prospective, Multicentre, Randomized, Open-label, Rater-blinded, Randomized Trial
Prospective, Multicenter, Open, End-point Blinded, Stratified Block Randomized, Parallel Positive Controlled Clinical Trial of Tenecteplase in Acute Ischemic Stroke With Large Vessel Occlusion Over Time Window
Who cites it
1 citing paper in PubMed.
- Discovery and validation of programmed cell death-associated key biomarker genes in ischemic stroke via ssGSEA/WGCNA and LASSO-SVM-RFE.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe association between time and reperfusion in an extended time window remains unexplored. This study aimed to investigate whether time delay was associated with reduced odds of reperfusion in patients with acute ischemic stroke treated with tenecteplase in the 4.5- to 24-hour time window, in the CHABLIS-T (Chinese Acute Tissue-Based Imaging Selection for Lysis in Stroke-Tenecteplase) trials.
methodsPatients from the CHABLIS-T and CHABLIS-T II trials treated with tenecteplase were included. Major reperfusion was assessed via follow-up perfusion imaging or digital subtraction angiography. Time intervals from symptom onset/last known well to hospital arrival/administration of tenecteplase were analyzed as continuous and categorical variables in multivariable logistic regression models. Subgroup analysis examined the consistency of the association across different patient characteristics.
resultsSixty-seven patients achieved postthrombolytic major reperfusion among the 199 patients included. Longer onset-to-arrival time was associated with lower odds of major reperfusion (continuous: odds ratio [OR], 0.98 per 10 minutes,
conclusionsTime delay was associated with reduced postthrombolytic reperfusion odds in patients with stroke treated with tenecteplase, especially in nonatherosclerotic cases. Prompt reperfusion remains essential, even in patients with benign perfusion profiles in an extended time window. REGISTRATION: URL: https://clinicalTrials.gov; URL: CHABLIS-T NCT04086147; CHABLIS-T II NCT04516993.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.